“Are Your Medications Being Controlled By Big Pharmaceuticals?”
The rising cost of prescription drugs has prompted insurance companies to rely more and more on exclusive deals with pharmacies and drug suppliers. These deals, known as preferred pharmacy networks, aim to cut down costs, but at what expense?
What Are Preferred Pharmacy Networks (PPNs)?
Preferred Pharmacy Networks (PPNs) are deals that insurers, like Manulife Financial Group and Canada Life, have with pharmacies to limit where patients can purchase their medication. While the insurers argue that PPNs can lead to savings on group benefits plan premiums, patient groups and independent pharmacists claim that these networks can ultimately restrict access to medications.
Restrictions Put on Patients
Kari Wutzke, a patient diagnosed with chronic pain and various conditions, has felt the impact of PPNs firsthand. In order to receive her tremfya prescription to treat her arthritis, she’s had to navigate the restrictions placed on where she can purchase her medication. Ultimately, these restrictions have led her to face an array of corporate relationships and indirect fees.
The Growing Prevalence of PPNs
It is concerning to note that PPNs have been increasingly prevalent in Canada, a trend that could impact the care received by patients. PPNs mainly cover expensive specialty drugs that treat conditions such as rheumatoid arthritis, Crohn’s disease, and multiple sclerosis. It can be challenging for consumers to navigate the complex system of PPNs, as they come in various forms and involve an array of healthcare providers and pharmacies.
Public Scrutiny and the Way Forward
The recent public outcry regarding the Manulife-Shoppers deal has reignited the debate on PPNs. With patient choice and access to medication at the forefront, it is crucial for insurance companies, pharmacies, and government officials to collaborate on regulations that balance cost-effective care with providing patients with the flexibility to receive adequate treatment. Regardless of the incentives of insurance companies, the welfare of the patient should always be the top priority. A thorough investigation into the overall impact of PPNs is required to ensure that patients receive the best possible care without limitations.
Reference
